# Zentaris IVF GmbH

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/zentaris-ivf-gmbh
Canonical HTML page: https://getbiobrief.com/entity/zentaris-ivf-gmbh

## Timeline

- **2026-03-05**: Strategic Update — COSCIENS announces cessation of funding for German biopharma subsidiaries.
- **2026-02**: Wuzhou Agreement — Distribution deal signed with Wuzhou Drug International Trading Limited.
- **2026-Q1**: FDA Type C Meeting — Regulatory feedback confirms significant hurdles for pediatric expansion.
- **2025-Q4**: DETECT Trial Results — Phase 3 trial for pediatric indication yields disappointing results.

## Recent coverage (1 stories)

### COSCIENS Abandons Biopharma Unit Following Macrilen Pediatric Setback
2026-03-06 01:04:28 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

COSCIENS Biopharma Inc. has announced a definitive strategic shift by ceasing all funding for its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. The decision triggers a structured insolvency process for the units following the failure of a Phase 3 pediatric trial for its flagship diagnostic, Macrilen.
Full story: https://getbiobrief.com/story/cosciens-biopharma-strategic-update-insolvency

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.